Item 1

Call to order

Item 2

Approval of minutes from July 28, 2017 (Vote required)

Item 3

Old business: Report on Health and Human Services Commission decisions on acceptance of the Drug Utilization Review (DUR) Board
recommendations from the July 28, 2017, meeting

Item 4

New business:
Public comment on drug classes and therapeutic and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL):
a. Androgenic agents
b. Antibiotics, GI
c. Antibiotics, topical
d. Antibiotics, vaginal
e. Antiemetic/antivertigo agents
f. Antifungals, oral
g. Antifungals, topical
h. Antihistamines, first generation
i. Antiparasitics, topical
j. Antipsychotics
k. Antivirals, oral/nasal
l. Antivirals, topical
m. Bile salts
n. Bone resorption suppression and related agents
o. Colony stimulating factors
p. Cytokine and CAM antagonists
q. Epinephrine, self-injected
r. GI motility, chronic
s. Growth hormone
t. Hepatitis C
u. Hypoglycemics, incretin mimetics/enhancers
v. Hypoglycemics, insulin and related
w. Hypoglycemics, meglitinides
x. Hypoglycemics, metformin
y. Hypoglycemics, TZD
z. Macrolides/ketolides
aa. Opiate dependence treatments
bb. Pediatric vitamin preparations
cc. Penicillins
dd. Stimulants and related agents
ee. Tetracyclines

Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:
ff. Analgesics, narcotics long / Morphabond ER
gg. Antihistamines, minimally sedating / Xyzal Solution OTC
hh. Antihistamines, minimally sedating / Xyzal Tablet OTC
ii. Antiparkinson's agents / Xadago

Items 5 & 6

5. Executive work session
Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section
354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open
Meetings Act.

6. Lunch

Item 7 (Part 1 of 2)

Announcements of drugs recommended for the Medicaid PDL

Item 8

*This item was joined in progress*

Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC
a. Report on recent retrospective DUR interventions sent:
i. Second-generation antipsychotics in youth
ii. Metabolic syndrome
iii. Stroke prevention 2017
iv. Polypharmacy 2017
v. Opioid use during pregnancy
b. Report on recent retrospective DUR interventions outcome:
i. Benzodiazepine anxiolytics and controlled sedative hypnotics
ii. Asthma disease management 2016
c. Retrospective DUR proposals: (Vote required)
i. Asthma disease management 2018 (/sites/default/files//documents/about-hhs/communications-events/meetingsevents/dur/110317/dur-agenda8ci-171103.pdf)
ii. Bipolar disorder management 2018 (/sites/default/files//documents/about-hhs/communications-events/meetingsevents/dur/110317/dur-agenda8cii-171103.pdf)
iii. Migraine prevention and treatment (/sites/default/files//documents/about-hhs/communications-events/meetingsevents/dur/110317/dur-agenda8ciii-171103.pdf)

Item 9

Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (Vote required)
a. Cytokine and CAM antagonists (/sites/default/files//documents/about-hhs/communications-events/meetings-events/dur/110317/duragenda9a-171103.pdf)
b. Gastrointestinal (GI) motility agents (/sites/default/files//documents/about-hhs/communications-events/meetings-events/dur/110317/duragenda9b-171103.pdf)
c. Ingrezza (Valbenazine) (/sites/default/files//documents/about-hhs/communications-events/meetings-events/dur/110317/dur-agenda9c-171103.pdf)
d. Keveyis ( Dichlorphenamide) (/sites/default/files//documents/about-hhs/communications-events/meetings-events/dur/110317/dur-agenda9d-171103.pdf)

Item 10

Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (Vote required)
a. Atypical antipsychotics (long-acting injectable) (/sites/default/files//documents/about hhs/communications-events/meetingsevents/dur/110317/dur-agenda10a-171103.pdf)
b. Atypical antipsychotics (oral) (/sites/default/files//documents/about-hhs/communicationsevents/meetings-events/dur/110317/dur-agenda10b-171103.pdf)
c. Nitazoxanide (Alinia) (/sites/default/files//documents/about-hhs/communications-events/meetings-events/dur/110317/dur-agenda10c-171103.pdf)
d. Promethazine use in children less than two years of age (/sites/default/files//documents/about-hhs/communications-events/meetingsevents/dur/110317/dur-agenda10d-171103.pdf)
e. Quetiapine (low-dose) (/sites/default/files//documents/about-hhs/communications-events/meetings events/dur/110317/dur-agenda10e-171103.pdf)

Item 7 (Part 2 of 2)

Announcements of drugs recommended for the Medicaid PDL

Items 11 & 12

11. Adjourn

12. Next meeting date: January 26, 2018